# RMGP Biopharma Investment Fund

> RMGP Biopharma Investment Fund is a VC fund backing Biotechnology and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026

RMGP Biopharma Investment Fund is an investment Fund

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 100% |
| Biopharma | 3 | 60% |
| Life Science | 2 | 40% |
| Health Care | 1 | 20% |
| Therapeutics | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Skip Therapeutics | Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations. |  | Seed | May 01, 2021 |  |
| JAMM Therapeutics | JAMM Therapeutics is a drug discovery company developing small molecule modulators for the treatment of systemic lupus erythematosus (SLE).A family of cytokines known as type I IFNs exhibits antiviral, antiproliferative, and immunomodulatory functions. All type I IFNs function by attaching to the same receptor complex, which has the IFNAR1 andIFNAR2 subunits. IFNAR1 polyubiquitination, which instructs the internalized receptor for destruction in the lysosome, is one of the mechanisms regulating type I IFN activation. IFNAR1's K63-conjugated polyubiquitin chain can be disassembled by the cytoplasmic complex DUB, also known as BRISC (BRCC36 isopeptidase complex), which stabilizes IFNAR1 and encourages IFN-dependent reactions. Both in humans and mice, type I IFNs play a key role in the pathogenesis of SLE. When SLE is produced in BRISC-deficient mice, the mice show improved clinical functioning, reduced IFN responses, and protection against immunopathology linked to IFN. |  | Seed | May 01, 2020 |  |
| Protekt Therapeutics | ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019. | $4.1M |  | Nov 12, 2019 |  |
| Pi Therapeutics | Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and hasoperated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer. | $19.7M | Series B | May 29, 2019 |  |
| Ramino Bio | Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around. |  | Seed | Sep 01, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [FutuRx](https://shizune.co/investors/profile/futurx) — VC Fund, 4 deals together
- [Israel Innovation Authority](https://shizune.co/investors/profile/israel-innovation-authority) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 2 deals together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 1 deal together
- [Bukwang Pharmaceutical Co](https://shizune.co/investors/profile/bukwang-pharmaceutical-co) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)
- [Biotech VC Funds in Middle East](https://shizune.co/investors/biotech-vc-funds-middle-east)
- [Biotech Investors in Israel](https://shizune.co/investors/biotech-investors-israel)
- [Biotech VC Funds in Israel](https://shizune.co/investors/biotech-vc-funds-israel)

## FAQ

### What does RMGP Biopharma Investment Fund invest in?

RMGP Biopharma Investment Fund invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did RMGP Biopharma Investment Fund last invest?

The most recent investment recorded for RMGP Biopharma Investment Fund closed in May 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co